Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
CHEK-ATP212 | Human | HEK293/Human GPC3 ΔHS Stable Cell Line |
Expression analysis of human GPC3 ΔHS on HEK293/Human GPC3 ΔHS Stable Cell Line by FACS.
Cell surface staining was performed on HEK293/Human GPC3 ΔHS Stable Cell Line or negative control cell using PE-labeled anti-human GPC3 antibody.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
GPC-3298306 | GPC-3298306 | Phase 2 Clinical | National Cancer Center Of Japan | Ovarian Neoplasms; Carcinoma, Hepatocellular | Details |
BOS-342 | PRS-342; BOS-342; PRS-342/BOS-342 | Phase 2 Clinical | Pieris Pharmaceuticals | Solid tumours; Carcinoma, Hepatocellular | Details |
BOXR-1030 | BOXR-1030 | Phase 2 Clinical | Unum Therapeutics Inc | Liver Neoplasms; Carcinoma, Merkel Cell; Lung Neoplasms; Carcinoma, Squamous Cell; Liposarcoma, Myxoid; Carcinoma, Hepatocellular | Details |
AZD-9793 | AZD9793; AZD-9793 | Phase 2 Clinical | Astrazeneca Plc | Carcinoma, Hepatocellular | Details |
CAR-T Cell Therapy Targeting GPC3(Pla General Hospital) | Phase 2 Clinical | Pla General Hospital | Carcinoma, Hepatocellular | Details | |
MRG-006A | MRG-006A; MRG-006; MRG006A | Phase 2 Clinical | Lepu Biopharma Co Ltd, Shanghai Miracogen Inc | Solid tumours; Neoplasms; Carcinoma, Hepatocellular | Details |
C-CAR031 CAR T-cell therapy (AbelZeta) | C-CAR031 | Phase 2 Clinical | Cellular Biomedicine (Shanghai) Co Ltd | Carcinoma, Hepatocellular | Details |
NY-303 | NY-303 | Phase 2 Clinical | NAYA Biosciences Inc | Solid tumours; Carcinoma, Hepatocellular | Details |
AZD-5851 | AZD-5851; AZD5851 | Phase 2 Clinical | Astrazeneca Plc | Carcinoma, Hepatocellular | Details |
SAR-444200 | SAR-444200 | Phase 2 Clinical | Sanofi | Solid tumours; Neoplasms | Details |
CMD-011 | CMD-011 | Phase 2 Clinical | Zhejiang Shimai Pharmaceutical Co Ltd | Liver Neoplasms; Carcinoma, Hepatocellular | Details |
CAR-GPC3 T-cell (Drum Tower Hospital) | Phase 2 Clinical | Nanjing Drum Tower Hospital | Carcinoma, Hepatocellular | Details | |
GPC3 CAR-T therapy (Hrain Biotechnology) | Phase 2 Clinical | Hrain Biotechnology Co Ltd | Carcinoma, Hepatocellular | Details | |
CM-350 | CM-350 | Phase 2 Clinical | Keymed Biosciences Co Ltd | Solid tumours | Details |
GPC3-CAR-T cell therapy(Origincell Medical Technology) | Ori-CAR-001; Ori-C101(OriCell) | Phase 2 Clinical | OriCell Therapeutics Co Ltd | Carcinoma, Hepatocellular | Details |
ECT-204 | JWATM-204; ECT-204 | Phase 2 Clinical | Eureka Therapeutics Inc, Jw Therapeutics (Shanghai) Co Ltd | Liver Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
Codrituzumab | GC-33; RG-7686; RO-5137382 | Phase 1 Clinical | Chugai Pharmaceutical Co Ltd, F. Hoffmann-La Roche Ltd | Solid tumours; Carcinoma, Hepatocellular | Details |
GPC3-T2 CAR-T cell therapy (The Second Affiliated Hospital of Guangzhou Medical University) | Phase 1 Clinical | Second Affiliated Hospital Of Guangzhou Medical University | Carcinoma, Squamous Cell; Carcinoma, Hepatocellular | Details | |
GLYCAR T cell therapy (Baylor College of Medicine) | GLYCAR | Phase 1 Clinical | Baylor College Of Medicine | Rhabdomyosarcoma; Liver Neoplasms; Hepatoblastoma; Rhabdoid Tumor; Wilms Tumor; Liposarcoma; Carcinoma, Hepatocellular; Endodermal Sinus Tumor | Details |
Anti-GPC3 CAR T-cell therapy (Carbiogene Therapeutics) | CBG166; CBG-166 | Phase 1 Clinical | Nanjing University, Carbiogene Therapeutics Co Ltd | Carcinoma, Hepatocellular | Details |
GPC3-CAR-T cell therapy | CSG-GPC-3; CAR-GPC3 T-cell; GPC3-CAR/CSG-GPC3; anti-GPC-3 CAR T; KJgpc3-001; CT-011 | Phase 1 Clinical | Carsgen Biomedicine (Shanghai) Co Ltd | Solid tumours; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular | Details |
Anti-GPC3 chimeric antigen receptor T cell therapy (Hunan Zhaotai Yongren Biotech/Guangdong Zhaotai Invivo Biomedicine) | Phase 1 Clinical | Hunan Zhaotai Yongren Biotech Co Ltd, Guangdong Zhaotai Invivo Biomedicine Co Ltd | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details | |
GPC3-T2-CAR-T | GPC3-T2-CAR-T | Phase 1 Clinical | Second Affiliated Hospital Of Guangzhou Medical University | Carcinoma, Hepatocellular | Details |
EU-307 | EU307 | Phase 1 Clinical | Eutilex | Liver Neoplasms; Carcinoma, Hepatocellular | Details |
Ori-CAR-002 | Ori-CAR-002; GPC3-CAR-Ori2 | Phase 1 Clinical | OriCell Therapeutics Co Ltd | Multiple Myeloma | Details |
SENTI-301 | SENTI-301; SENTI-301A; SN301A | Phase 1 Clinical | Senti Biosciences Inc | Liver Neoplasms; Carcinoma, Hepatocellular | Details |
MT-303(Myeloid) | MT-303(Myeloid) | Phase 1 Clinical | Myeloid Therapeutics Inc | Carcinoma, Hepatocellular | Details |
68Ga-aGPC3-scFv/Fab | 68Ga-aGPC3-scFv/Fab | Phase 1 Clinical | Wuhan Union Hospital | Liver Neoplasms | Details |
BGB-B2033 | BGB-B2033; BGB-B-2033 | Phase 1 Clinical | Beigene Guangzhou Biologics Manufacturing Co Ltd | Solid tumours; Stomach Neoplasms; Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
BC-2027 | BC2027; BC-2027 | Phase 1 Clinical | Wuxi BioCity | Liver Neoplasms; Solid tumours | Details |
JMT-106 | JMT106; JMT-106 | Phase 1 Clinical | CSPC Pharmaceutical Group Ltd | Solid tumours | Details |
AST-201 (Aptamer Sciences) | AST-201(Aptamer Sciences) | Phase 1 Clinical | Aptamer Sciences Inc | Liver Neoplasms; Solid tumours; Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
GPC3/Mesothelin-CAR-γδT Cells therapy(Second Affiliated Hospital Of Guangzhou Medical University) | Phase 1 Clinical | Second Affiliated Hospital Of Guangzhou Medical University | Solid tumours; Liver Neoplasms; Pancreatic Neoplasms; Mesothelioma; Lung Neoplasms | Details | |
RYZ-801 | RYZ-801(225Ac); RYZ-801; ABZ-706; 225Ac-GPC3 | Phase 1 Clinical | PeptiDream Inc, RayzeBio Inc | Carcinoma, Hepatocellular | Details |
NWRD-06 | NWRD-06; NWRD06 | Phase 1 Clinical | Newish Technology (Beijing) Co Ltd | Carcinoma, Hepatocellular | Details |
GPC3-targeted CAR-T (Peking University) | Phase 1 Clinical | Peking University | Carcinoma, Hepatocellular | Details | |
CAR (hYP7)-T cells (National Cancer Institute) | Phase 1 Clinical | National Cancer Institute | Carcinoma, Hepatocellular | Details | |
TC-CAR-031 | C-CAR-031; TC-CAR-031; TC-CAR031; C-CAR031 | Phase 1 Clinical | Zhejiang University, Cellular Biomedicine Group Inc | Carcinoma, Hepatocellular | Details |
IM-83 CAR-T cell therapy | IM-83; IM83 | Phase 1 Clinical | Beijing Immunochina Medical Science & Technology Co Ltd | Liver Neoplasms; Neoplasms; Osteosarcoma; Carcinoma, Hepatocellular | Details |
CT-017 | CT-017 | Phase 1 Clinical | Carsgen Biomedicine (Shanghai) Co Ltd | Carcinoma, Hepatocellular | Details |
JWATM-214 | JWATM-214; JWATM214 | Phase 1 Clinical | Suzhou Yaomingjunuo Biotechnology Co Ltd | Liver Neoplasms; Carcinoma, Hepatocellular | Details |
TH-012(Bangentai Biomedical) | TH-012 | Phase 1 Clinical | Shandong Bangentai Biomedical Tech Group Co Ltd | Stomach Neoplasms; Pancreatic Neoplasms | Details |
B010-A | B010-A | Phase 1 Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Carcinoma, Hepatocellular | Details |
CT-0180 | CT-0180 | Phase 1 Clinical | CARsgen Therapeutics Holdings Ltd | Carcinoma, Hepatocellular | Details |
ERY-974 | ERY-974 | Phase 1 Clinical | Chugai Pharmaceutical Co Ltd | Solid tumours; Carcinoma, Hepatocellular | Details |
TAK-102 | TAK-102; NIB-102 | Phase 1 Clinical | Noile-Immune Biotech Inc | Solid tumours | Details |
HRAIN-011 | HRAIN-011 | Clinical | Hrain Biotechnology Co Ltd | Carcinoma, Hepatocellular | Details |
Anti-GPC3-IRDye800CW | Clinical | Chinese Academy Of Sciences | Details |
This web search service is supported by Google Inc.